{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-027642","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2026-07-06T21:17:19+00:00","discovered_at":"2026-07-06T21:18:00.259605+00:00","generated_at":"2026-07-06T21:18:05.814008+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Vertex to acquire Crinetics for $85/share, ~$10B equity value, adding PALSONIFY and atumelnant","bullets":["Vertex to acquire Crinetics for $85.00 per share in cash, total equity value ~$10.0B (~$8.8B net of cash).","Crinetics' PALSONIFY (once-daily oral for acromegaly) launched in 2025; atumelnant (ACTH receptor antagonist) in Phase 3 for CAH.","Transaction unanimously approved by both boards; expected to close in Q3 2026, subject to stockholder and regulatory approvals.","Vertex plans to finance with cash on hand and $4.5B bridge loan from Bank of America and Morgan Stanley.","Termination fee of ~$350M payable by Crinetics under certain circumstances."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-027642","json":"https://secwatch.observer/filing/0001140361-26-027642.json","markdown":"https://secwatch.observer/filing/0001140361-26-027642.md","text":"https://secwatch.observer/filing/0001140361-26-027642.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000114036126027642/0001140361-26-027642-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000114036126027642/ef20077399_form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-06T21:18:05.814008+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}